<DOC>
	<DOCNO>NCT02114658</DOCNO>
	<brief_summary>The objective study evaluate safety , efficacy pharmacokinetics sorafenib treatment Japanese patient anaplastic thyroid carcinoma ( ATC ) locally advanced metastatic medullary thyroid carcinoma ( MTC ) .</brief_summary>
	<brief_title>Sorafenib Phase II Study Japanese Anaplastic Medullary Thyroid Carcinoma Patients</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Thyroid Diseases</mesh_term>
	<mesh_term>Thyroid Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Neuroendocrine</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Japanese patient ATC ( Anaplastic thyroid carcinoma ) locally advanced metastatic MTC ( medullary thyroid carcinoma ) Not candidate surgery radiotherapy curative intent Histologically cytologically confirm ATC MTC Measurable nonmeasurable disease ( clinically evaluable ) accord RECIST 1.1 . Age &gt; = 18 year Adequate bone marrow , liver renal function conduct within 14 day prior treatment Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) 0 1 Life expectancy least 12 week Histologic subtypes thyroid cancer anaplastic medullary carcinoma Prior anticancer treatment tyrosine kinase inhibitor , monoclonal antibody ( licensed investigational ) target VEGF VEGF ( vascular endothelial growth factor ) receptor target agent Prior chemotherapy thyroid cancer ( one regimen allow ) Major surgery , open biopsy , significant traumatic injury within 30 day prior enrollment study . Subjects tracheal , bronchial esophageal infiltration significant risk bleed without received local treatment prior enrollment study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Anaplastic medullary thyroid carcinoma</keyword>
	<keyword>Thyroid Neoplasms</keyword>
</DOC>